Table 1.
Characteristics of studies reporting body weight and/or body mass index (BMI) pre- and post-tumour necrosis alpha (TNF-α) inhibitor commencement.
| Authors | Study design | Disease | Time-frame (weeks) | N | Medication (dose) | Gender (M) | Age (SD) | SMCC Weight | SMCC BMI | Other meds (N) | Summary |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Csontos et al. (2016) | Prospective | IBD | 12 | 40 | Adalimumab (160/80/40mg) Infliximab (5mg/kg) |
8 (16) 8 (8) |
32.3 (14.4) 35.1 (10.5) |
-0.73 [-1.18, -0.28] -0.59 [-1.12, -0.06] |
-0.71 [-1.16, -0.27] -0.66 [-1.20, -0.12] |
5-ASA Azathioprine Steroids |
Weight ↑ Lean muscle ↑ |
| De Oliveira et al. (2008) | Prospective | PsO | 22 | 19 | Infliximab (5mg/kg) | 8 (11) | -0.25 [-0.70, 0.21] | Weight ↑ | |||
| Derdemezis et al. (2010) | Prospective | RA | 26 | 30 | Infliximab (3mg/kg) | 30 (0) | 51.8 (14.4) | 0.42 [00.4, 0.79] | Methotrexate Prednisolone |
Weight ↔ | |
| Di Renzo et al. (2011) | Prospective | PsO | 24 | 40 | Etanercept Infliximab |
-0.37 [-0.69, -0.05] | -0.38 [-0.70, -0.06] | Weight ↑ Lean mass ↑ Total fat mass ↑ |
|||
| Dos Santos et al. (2017) | Prospective | CD | 26 | 23 | Infliximab (5mg/kg) | 12 (11) | 42 (12) | -0.60 [-1.04, -0.15] | -0.58 [-1.02, -0.14] | Weight ↑ Lean mass ↑ Total fat mass ↑ Waist circum. ↑ |
|
| Ehsani et al. (2016) | Prospective | PsO | 26 | 25 | Infliximab | 7 (18) | 36.9 (13.3) | -1.14 [-1.64, -0.64] | BMI ↑ | ||
| Ersozlu Bozkirli et al. (2014) | Prospective | 12 | 30 | Infliximab (5mg/kg) | 7 (23) | 34.3 (10.2) | -0.28 [-0.64, 0.09] | -0.26 [-0.62, 0.10] | Weight ↔ | ||
| Esposito et al. (2009) | Retrospective | RA | 26 | 100 | Etanercept | 34 (68) | 43.8 | -0.58 [-0.79, -0.37] | -0.54 [-0.75, -0.33] | Weight ↑ | |
| Ferraz-Amaro et al. (2011) | RA | 52 | 16 | -0.54 [-1.07, -0.02] | BMI ↑ | ||||||
| Franchimont et al. (2005) | Prospective | CD | 4 | 20 | Infliximab | 8 (12) | -0.14 [-0.58, 0.30] | -0.54 [1.07, -0.02] | Prednisolone (8) | Weight ↑ | |
| Gisondi et al. (2008) | Retrospective | PsO | 26 | 98 | Etanercept (25mg) Infliximab (5mg/kg) |
50.2 (11.1) 46.8 (11.2) |
-0.28 [-0.54, -0.01] -0.44 [-0.76, -0.11] |
-0.23 [-0.49, 0.03] -0.49 [-0.82, -0.16] |
Weight ↑ BMI ↑ |
||
| Kopec-Medrek et al. (2012) | Prospective | RA | 8 | 16 | Infliximab (3mg/kg) | 16 (0) | -0.26 [-0.76, 0.24] | BMI ↔ | |||
| Koutroubakis et al. (2009) | Prospective | IBD | 14 | 22 | Infliximab (5mg/kg) | 8 (14) | 38.6 | 3.33 [2.26, 4.40] | Prednisolone 5-ASA Azathioprine Methotrexate Salazopyrine Antibiotics |
BMI ↑ | |
| Magiera et al. (2013) | Prospective | RA | 53 | 18 | Infliximab (3mg/kg) | 18 (0) | -0.17 [-0.64, 0.29] | ||||
| Mahe et al. (2014) | Prospective | PsO | 52 | 191 | Infliximab (5mg/kg) | 60 (131) | 46.9 (12.8) | -0.17 [-0.32, -0.03] | Methotrexate (32) | Weight ↔ | |
| Marcora et al. (2006) | RCT | RA | 24 | 12 | Etanercept | 9 (3) | 54 (11) | -0.18 [-0.75, 0.39] | Weight ↔ | ||
| Mathieu et al. (2013) | Prospective | AS | 52 | 49 | Adalimumab Infliximab Etanercept |
19 (30) | 46.9 (12.1) | 0.16 [-0.13, 0.44] | Anti-hypertensive (10) | BMI ↔ | |
| Metsios et al. (2007) | Prospective | RA | 12 | 20 | 10 (10) | 0.10 [-.34, 0.54] | 0.11 [-0.33, 0.55] | Weight ↔ Total body fat ↔ Truncal fat ↑ |
|||
| Parmentier-Decrucq et al. (2009) | Prospective | CD | 8 | 21 | Infliximab (5mg/kg) | 13(8) | 32 (8) | 1.49 [0.87, 2.11] | Corticosteroids (30) Methotrexate or Azathioprine (78) |
BMI ↑ | |
| Popa et al. (2009) | Prospective | RA | 26 | 58 | Infliximab (3mg/kg) | 42 (16) | 56 (11) | 0.07 [-0.19, 0.32] | 0.00 [-0.26, 0.26] | Corticosteroids Methotrexate Salazopyrine |
Weight ↔ BMI ↔ |
| Sandoo et al. (2012) | Prospective | RA | 12 | 23 | 15 (8) | 54 (15) | -0.04 [-0.44, 0.37] | BMI ↔ | |||
| Saraceno et al. (2008) | Retrospective | PsA | 48 | 305050 | Adalimumab (40mg) Infliximab (3mg/kg) Etanercept (50mg) |
114 (116) | 46.7 | -0.53 [-0.91, -0.14] -0.25 [-0.53, 0.03] -0.32 [-0.61, -0.04] |
-0.49 [-0.86, -0.11] -0.23 [-0.51, 0.05] -0.29 [-0.57, -0.00] |
Weight ↑ | |
| Tan et al. (2013) | Retrospective | PsO | 48 | 54 63 61 |
Adalimumab Infliximab Etanercept |
18 (36) 12 (51) 16 (45) |
49 (11.7) 49.7 (11.8) 52.3 (11.3) |
0.04 [-0.22, 0.31] -0.25 -0.50, 0.01] 0.51 [0.24, 0.78] |
Weight ↑ BMI ↑ |
||
| Toussirot et al. (2014) | Prospective | RA | 104 | 20 | Adalimumab (40mg) Infliximab (3-5mg/kg) Etanercept (50mg) |
6 (14) | 48.6 | -0.15 [-0.75, 0.44] -0.48 [-1.68, 0.71] -0.29 [-1.11, 0.53] |
-0.11 [-0.70, 0.48] -0.49 [-1.69, 0.70] -0.41, -1.24, 0.42] |
Methotrexate (6) Leflunomide (2) Corticosteroids (9) |
Weight ↑ Total fat mass ↑ |
| Wiedenmann et al. (2008) | RCT | Cancer | 8 | 2828 | Infliximab (3mg/kg) Infliximab (5mg/kg) | 63.163.6 | 0.63 [0.22, 1.03] -4.42 [-5.64, -3.20] |
0.34 [-0.04, 0.72] -0.15 [-0.52, 0.22] |
Lean body mass ↔ | ||
| Younis et al. (2013) | Prospective | SpA | 16 | 16 | Infliximab | 53 | -0.07 [-0.57, 0.42] | -0.05 [-0.54, 0.44] | Weight ↔ BMI ↔ |
IBD, inflammatory bowel disease; RA, rheumatoid arthritis; PsO, psoriasis; PsA, psoriatic arthritis; CD, Crohn’s disease; SpA, spondylarthritis; AS, ankylosing spondylitis.
↑ = increase; ↔ = no change.